NPI 1730101668: Open Payments
NPI 1730101668. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$213 in 10 payments from 4 companies in 2025. Trend: 2023 $1,632 · 2024 $1,908 · 2025 $213
Food & beverage: $213
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $89 |
| Lundbeck LLC | 2 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
Products named: INGREZZA, REXULTI, CAPLYTA, AUSTEDO XR, UZEDY.
